Relationships between the gene polymorphisms of drug metabolizing enzymes and the outcome of the first induction chemotherapy in patients with de novo acute myeloid leukemia.
- Author:
Na WANG
1
;
Jun-Ling HAN
;
Ying-Chang MI
;
Zhi-Jian XIAO
;
Si-Zhou FENG
;
Yu-Ling ZHOU
;
Jian-Xiang WANG
;
Ming-Zhe HAN
Author Information
1. Chinese Academy of Medical Sciences, Tianjin 300020, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antineoplastic Agents;
therapeutic use;
Child;
Cytochrome P-450 CYP2D6;
genetics;
Female;
Genotype;
Glutathione Transferase;
genetics;
Humans;
Leukemia, Myeloid, Acute;
drug therapy;
enzymology;
genetics;
Male;
Middle Aged;
Polymorphism, Single Nucleotide;
Remission Induction;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2011;19(2):327-331
- CountryChina
- Language:Chinese
-
Abstract:
The objective of this study was to investigate the correlation between the gene polymorphisms of drug metabolizing enzymes and the outcome of the first induction chemotherapy in patients with de novo acute myeloid leukemia (AML). 113 de novo AML patients were enrolled in this study. The genotypes of 11 single nucleotide polymorphisms (SNP) in drug metabolizing enzymes were detected by the SNPstream(®) Genotyping System. The correlation between the distribution of genotypes and the complete remission rate of first induction chemotherapy was analyzed by logical regression. The results showed that patients with variant genotype of CYP2D6 (rs16947) had a lower complete remission (CR) rate, as compared to those with wild type (p = 0.033, OR = 0.32, 95%CI 0.112 - 0.915); meanwhile the patients with variant genotype of GSTO2 (rs156697) had a higher CR rate as compared to those with wild type (p = 0.011, OR = 3.023, 95%CI 1.289 - 7.089). Combined analysis of the above polymorphisms, showed that patients with variant genotype of CYP2D6 and wild genotype of GSTO2 (V + W) had lower CR rates in comparison to patients with wild genotypes of both polymorphisms (p = 0.017, OR = 0.183, 95%CI 0.045 - 0.735). It is concluded that CYP2D6 (rs16947) and GSTO2 (rs156697) polymorphisms are independent factors influencing CR rates of the first induction chemotherapy in de novo AML patients.
